$1.65
−4.62%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$1.78
From 52W high−84.48%
Volume36421.00
Market cap$23.86M
P/E (TTM)—
P/S (TTM)12.1x
Div yield—
Key dataSep 18, 2026
Open
$1.78
From 52W high
−84.48%
Volume
36421.00
Market cap
$23.86M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.4x
P/E (TTM)
—
RSI (14)
29.0
MomentumView details →
1D Return
−4.62%
YTD Return
−67.05%
SummaryUpdated Jun 1, 2026
Radiopharm Theranostics Limited (ASX:RAD) is a clinical-stage biotechnology company founded in 2021 and based in Carlton, Australia. The company recently went public in December 2024, representing one of the newest entrants in the radiopharmaceutical space. Radiopharm focuses on developing next-generation radiopharmaceutical products that combine diagnostic imaging with targeted therapeutic applications, addressing areas of high unmet medical need in oncology.
Similar companies
Latest newsMore news →
Radiopharm Theranostics dosed the first patient in the second cohort of its Phase 1/2a clinical trial of BetaBart (RV-01), a radiopharmaceutical therapeutic for B7-H3 expressing solid tumors, at a 70 mCi dose, marking the first such therapeutic developed in its joint venture with MD Anderson Cancer Center.25d agoRadiopharm Theranostics' ADR shares fell 8.4% during mid-day trading on Thursday, trading as low as $2.23 and last at $2.29, with volume down 41% from average.30d agoRadiopharm Theranostics announces a registered direct offering of 1,281,646 ADSs at US$3.16 per ADS to raise approximately US$4.1 million from U.S. institutional investors.58d ago